Novo Nordisk’s “next-generation” basal insulin degludec. Novo Nordisk has released promising data from a 7,000-participant clinical trial for its next-generation basal...
Diabetes Drug News
Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.
Metformin Insulin SGLT-2 GLP-1 DPP-4 Combo drugs Sulfonylureas TZDs
31 readers recommended
27 readers recommended
Just in time for the New Year, Kelly reveals good news on obesity therapies and insulin delivery devices.
46 readers recommended
Novo Nordisk’s once daily GLP-1 agonist Victoza (above) provided slightly better improvements in blood glucose control than Amylin/Eli Lilly/ Alkermes’s once weekly GLP-...
37 readers recommended
A thorough review and “how-to” on the drug Symlin (Amylin’s pramlintide).
38 readers recommended
Last week, in a surprise and, in our view, disappointing move, the FDA decided to not approve Bydureon, a once-weekly GLP-1 agonist, for use in the United States despite...
44 readers recommended
For type 2 patients, the use of GLP-1 agonists (such as Victoza and Byetta ) can often lead to significant improvements in blood glucose control and weight loss with...
28 readers recommended
A girl can dream, right? (...of cures and new insulins...)
43 readers recommended
David Simmons, President and General Manager of Pfizer’s Established Products Business Unit, and Kiran Mazumdar-Shaw, Chairman and Managing Director of Biocon, shake...
26 readers recommended
Kelly muses on the future of GLP-1 agonists and bariatric surgery.
29 readers recommended
We recently reviewed three drug candidates for the treatment of obesity – Contrave, lorcaserin, and Qnexa. All three drugs in development: they all have been submitted...
43 readers recommended
After a day of deliberation earlier this month, a recent FDA advisory committee voted 13 to 7 to recommend approval of Contrave, a novel weight-loss drug made by...
40 readers recommended
Earlier this month, the FDA approved the once-daily oral drug Tradjenta (Boehringer Ingelheim and Eli Lilly’s linagliptin) for type 2 diabetes. Tradjenta belongs to the...
39 readers recommended
Obesity expert Dr. Lee Kaplan of Massachusetts General Hospital tells us how we may be able to bypass the bypass…
27 readers recommended
In mid-November, Santarus Inc. announced the launch of Cycloset, a novel, weight-neutral, glucose-lowering drug for type 2 diabetes. Cycloset is a quick-release...
45 readers recommended
Puzzled by the recent FDA decisions? Dr. Sanjay Kaul discusses the regulatory environment for diabetes and obesity medications.
29 readers recommended
Late last year, we found out about a new drug being developed by Reata Pharmaceuticals for the treatment of chronic kidney disease (CKD), a disorder that occurs more...
48 readers recommended
While Lantus (Sanofi’s insulin glargine) is the current standard for basal insulins, companies are still investing significant efforts to develop even better long-acting...
34 readers recommended
At EASD, Cellnovo announced that it had received approval in Europe for its new insulin patch pump. It will be launched soon in the UK, and its submission to the FDA is...
56 readers recommended
Want faster acting insulin? CDE Gary Scheiner shows you some options with five innovative tips that you may want to consider…
54 readers recommended
In October 2010, Biocon, an Indian pharmaceutical company, and Pfizer partnered to develop and market biosimilar insulin analogs (see NewNowNext in diaTribe #26). A...